SCOTUS to hear gene patent suit

The U.S. Supreme Court agreed to hear Association for Molecular Pathology, et al. v. Myriad Genetics, Inc., et al., a suit about the eligibility of genes for patenting. The court will review a 2-1 August ruling by the U.S. Court of Appeals for the Federal Circuit that said composition and method claims in patents from Myriad Genetics Inc. (NASDAQ:MYGN) covering the breast cancer 1 early onset (BRCA1) and BRCA2 genes are valid under Section 101 of the Patent Act. Myriad was down $1.13 to $28.72 on Friday (see BioCentury Extra, Sept. 25). ...